Biondvax Pharm (BVAXF) 0.2000 $BVAXF 2013 Report on the

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biondvax Pharm (BVAXF) 0.2000 $BVAXF

2013 Report on the International Vaccine Market - Global Forecasts To 2022
M2 - Fri Jan 03, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gg35h/vaccine_market_by) has announced the addition of the "2013 Report on the International Vaccine Market - Global Forecasts To 2022" report to their offering. In general, the vaccine technology market is largely perceived negatively as a low-profit venture owing to the domination of top five companies, namely, Sanofi (France), Glaxo Smithkline (U.K.), Merck (U.S.), Pfizer (U.S.), and Novartis (Switzerland). Furthermore, a strong patent portfolio and the need for large investments towards vaccine development have limited the scope of entry for new companies. This report analyzes the vaccine technology market both in terms of qualitative (technological) and quantitative (revenue) perspectives. The technological analysis includes a discussion on different classes of vaccines, vaccine adjuvants, and commercially available products. The market revenue analysis includes market segmentation and the expected market position by 2022, with the projected growth rate. The vaccine market is classified by technology class, types, end users, disease indication, and geography. The details on the emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are discussed. Furthermore, key research centers, with their critical areas of research in the vaccine space, have been provided. An overview of regulations across various geographical regions has been covered. The complete value chain of the vaccine market is schematically represented and the significance of each stakeholder has been briefed. As well as technological and market analysis, the investor climate has been assessed by tracking the complete investor network and collecting data on funds/grants and investments made towards vaccine development. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Technology Snapshot (Page No. - 31) 4 Vaccine Research Portfolio 5 Value Chain Analysis 6 Market Landscape 7 Technology Adoption 8 Investment Analysis 9 Competitive Landscape 10 Regulatory Landscape 11 Patent Analysis 12 Analyst Recommendations 13 Company Profiles Companies Mentioned: - Aduro Biotech - Alphavax - Antigen Express, INC - Bavarian Nordic - Biondvax Pharmaceuticals LTD - Genticel - Glaxo Smithkline PLC - Immune Targeting Systems (ITS) - Immunobiology LTD - Liquidia Technologies - Merck & CO, INC - Novartis AG - Pfizer, INC - Prokarium - Sanofi For more information visit http://www.researchandmarkets.com/research/3g..._market_by

Global Vaccine Market by Technology & Types, Various Classes & Indications 2013-2022
M2 - Tue Oct 15, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bsp29k/vaccine_market_by) has announced the addition of the "Global Vaccine Market by Technology & Types, Various Classes & Indications 2013-2022" report to their offering. The global vaccine technology market is anticipated to reach around $84 billion by 2022, growing at a CAGR of 11.36%. The vaccine market is divided by technology class (Live/Attenuated, Toxoid, Conjugate, Sub-Unit, Recombinant Vector, DNA, Synthetic, and Dentritic Vaccines), types (Preventive and Therapeutic), end users (Pediatric and Adult), disease indication (Infectious Diseases, Cancer, Allergies, and Others - Diabetes, Cardiovascular Diseases), and geography (North America, Europe, Asia, and Rest of the World). Furthermore, each technology class, type, end user, and disease indication segment is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned disease indication segments, infectious disease vaccines are the largest revenue segment; however, cancer vaccines will be the fastest-growing segment with the highest CAGR. The potential growth of the market is attributed towards therapeutic vaccines, allergy vaccines, and emerging-disease vaccines. Improved understanding of immunology, new technological breakthroughs in the development of a new class of vaccines, namely, recombinant vector vaccines, DNA vaccines, and dendritic vaccines coupled with excellent distribution channels are propelling the growth of this market. Furthermore, a large population base in emerging economies and a high prevalence of diseases is driving the market, which is expected to remain consistent in the coming years. Largely popular as the biological preparation exclusively for the prevention of diseases, vaccines are now emerging as therapeutic agents for improving the immune system. This is adding a new dimension to the vaccine industry, opening doors for the treatment of various ailments, especially cancer, cardiovascular disease, diabetes, and smoke cessation. These opportunities have also paved the way for the entry of new companies and for the development of newer technology platforms. Furthermore, new emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are paving the way for the development of new effective vaccines capable of addressing current and emerging infectious diseases and cancers. North America (42%) is a significant contributor, followed by Europe (36%), due to the highly structured healthcare reimbursement policies and the high purchasing power of costly vaccines. The new markets for vaccine are expected to grow at a vigorous pace in emerging economies such as China, India, and other regions in Asia-Pacific and untapped markets in Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics. Scope of the Report Technology Class - Live - Toxoid - Conjugate - Sub-Unit - Recombinant Vector Vaccines - DNA Vaccines - Synthetic Vaccines - Dentritic Vaccines Types - Preventive - Therapeutic End Users - Pediatric - Adult Disease Indication - Infectious Diseases - Cancer - Allergies - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Technology Snapshot 4 Vaccine Research Portfolio 5 Value Chain Analysis 6 Market Landscape 7 Technology Adoption 8 Investment Analysis 9 Competitive Landscape 10 Regulatory Landscape 11 Patent Analysis 12 Analyst Recommendations 13 Company Profiles - Aduro Biotech - Alphavax - Antigen Express, INC - Bavarian Nordic - Biondvax Pharmaceuticals LTD - Genticel - Glaxo Smithkline PLC - Immune Targeting Systems (ITS) - Immunobiology LTD - Liquidia Technologies - Merck & CO, INC - Novartis AG - Pfizer, INC - Prokarium - Sanofi For more information visit http://www.researchandmarkets.com/research/bs..._market_by

Vaccine Market by Technology & Types, Various Classes & Indications - Global Forecasts To 2022
M2 - Wed Aug 14, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhq7rz/vaccine_market_by) has announced the addition of the "Vaccine Market by Technology & Types, Various Classes & Indications - Global Forecasts To 2022" report to their offering. The vaccine technology market is an established segment and is widely accepted as an indispensable division of the healthcare industry. It is poised to grow rapidly by addressing the following issues: emerging infectious agents, various types of cancer, allergies, cardiovascular diseases, diabetes, smoke cessation, and neurodegenerative disorders. The global vaccine market is estimated at $32.05 billion in 2013 and is expected to reach $84.44 billion by 2022. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Technology Snapshot 4 Vaccine Research Portfolio 4.1 Global Research Portfolio - Research And Development Network 4.2 Emerging Approaches To Vaccine Developments 4.3 Key Research Centres 5 Value Chain Analysis 5.1 Overview 5.2 Cold Chain Management 5.3 Key Stakeholders 5.4 Gap Analysis 5.5 Porters Five Force Analysis 6 Market Landscape 7 Technology Adoption 7.1 Factors That Drive Adoption Of Vaccine Technologies 7.2 U.S. & Canada 7.3 U.K, Germany, France, Italy 7.4 China, India 7.5 Australia & Africa 8 Investment Analysis 8.1 Investor Network 8.2 Investment Funding Analysis 8.3 Top Funding Organizations 9 Competitive Landscape 9.1 Competitive Landscape Analysis - Overview 9.2 Key Acquisitions/Partnerships/Agreements/Collaborations (2012 - 2013) 9.3 Vaccine Candidates In Pipeline - Allergy 9.4 Vaccine Candidates In Pipeline - Cancer 9.5 Vaccine Candidates In Pipeline - Infectious Diseases 9.6 Vaccine Candidates In Pipeline - Others 10 Regulatory Landscape 10.1 Regulatory Landscape - Overview 10.2 Regulations - Geographic 11 Patent Analysis 11.1 Patent Analysis - Overview 11.2 Patent Analysis By Company 12 Analyst Recommendations 12.1 Introduction 12.2 Technology Management Strategies 13 Company Profiles 14 Appendix Companies Mentioned - Aduro Biotech - Alphavax - Antigen Express, INC - Bavarian Nordic - Biondvax Pharmaceuticals LTD - Genticel - Glaxo Smithkline PLC - Immune Targeting Systems (ITS) - Immunobiology LTD - Liquidia Technologies - Merck & CO, INC - Novartis AG - Pfizer, INC - Prokarium - Sanofi For more information visit http://www.researchandmarkets.com/research/zh..._market_by
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 61

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 106

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 61

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 104

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 182

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 66

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 173

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 125

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 140

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading

Top 5 Most Recently Viewed Articles

Ford Motor Company Faces Legal Challenges: Key Insights

Updated Category News Views 119

Understanding the Legal Landscape for Ford Motor Company As investors navigate the intricate world of stock ownership, recent events surrounding Ford Motor Company have raised eyebrows. The company currently finds itself at the center of a class action lawsuit involving shareholders who acquired stock during a specific period. Class Action Overview and Important Dates...

Continue Reading
Transforming the Specialty Fats and Oils Industry for Success

Updated Category News Views 188

A Deep Dive into the Specialty Fats and Oils Market The landscape of the specialty fats and oils market is rapidly transforming, growing from its valuation of US$ 16.12 billion in the preceding year to a staggering US$ 31.69 billion by 2033, marking a robust CAGR of 7.8% during the next financial stretch. This growth signals a significant shift in industry dynamics and...

Continue Reading
C3.ai: Analyzing Current Trends in the Options Market

Updated Category News Views 241

Current Sentiment on C3.ai Recently, well-known investors—often referred to as whales—have taken a decidedly negative stance towards C3.ai. This growing skepticism stems from the history of options involving the company's stock. An analysis of C3.ai's (AI) trading patterns uncovered nine notable trades. Digging deeper into these transactions shows that only 22% of...

Continue Reading
CytomX Therapeutics Completes $100 Million Stock Offering

Updated Category News Views 315

CytomX Therapeutics Completes $100 Million Stock Offering CytomX Therapeutics, Inc. (NASDAQ: CTMX), based in South San Francisco, has just announced the pricing of an extensive stock offering. The company is set to offer 76,923,076 shares of its common stock at a price of $1.30 per share. This significant transaction aims to raise approximately $100 million and is being...

Continue Reading
Wall Street's Bullish Coverage Initiation Highlights for NKE and Others

Updated Category News Views 120

Wall Street Analysts Initiate Coverage on Key Stocks In a dynamic market landscape, top analysts have recently adjusted their ratings on several prominent companies. Their insights provide a glimpse into potential future performance for investors. Today, we spotlight these analyst ratings and what they mean for some notable stocks. NIKE, Inc. (NKE) Coverage by Needham...

Continue Reading